Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion
NASDAQ:FDMT

4D Molecular Therapeutics Q3 2026 Earnings Date & Estimates

4D Molecular Therapeutics logo
$13.10 +0.81 (+6.59%)
Closing price 04:00 PM Eastern
Extended Trading
$13.10 +0.01 (+0.04%)
As of 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

4D Molecular Therapeutics is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026. The conference call is scheduled for November 9, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from 4D Molecular Therapeutics in Q3 2026

4D Molecular Therapeutics is expected to post earnings of -$1.04 per share on revenue of $3.54 million. In the same quarter a year earlier 4D Molecular Therapeutics reported -$1.01 per share on revenue of $0.09 million. 4D Molecular Therapeutics last reported on August 13, 2026, posting -$1.04 per share and missing the -$1.02 consensus estimate. 4D Molecular Therapeutics has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$1.04
Expected Revenue
$3.54 million
Prior-Year EPS
-$1.01
Prior-Year Revenue
$0.09 million
Expected Revenue Growth
+3,833.3%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$1.04 (Missed by -$0.02)
Last Quarter Revenue
$3.78 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

4D Molecular Therapeutics Q3 2026 Earnings FAQ

4D Molecular Therapeutics (NASDAQ:FDMT) is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

4D Molecular Therapeutics' Q3 2026 earnings conference call is scheduled for Monday, November 9, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect 4D Molecular Therapeutics to post earnings of -$1.04 per share for Q3 2026.

The consensus revenue estimate for 4D Molecular Therapeutics is $3.54 million for Q3 2026.

4D Molecular Therapeutics Earnings Headlines

Comparing 4D Molecular Therapeutics (NASDAQ:FDMT) and Sangamo Therapeutics (NASDAQ:SGMO)
October 19 at 4:58 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31133474
4DMT Announces New Employment Inducement Grants
October 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/16/3382788/0/en/4dmt-announces-new-employment-inducement-grants.html
The Iran War Isn’t Chaos. It’s Strategy.
Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congressmen no cameras, no staff. What he found afterward points to a coordinated Two-Front Economic War already in motion, according to his research at Behind the Markets.tc pixel
October 20 at 1:00 AM  |  Behind the Markets (Ad)
4D Molecular Therapeutics Inc (FDMT)
October 16, 2026  |  au.investing.comhttps://au.investing.com/equities/4d-molecular-therapeutics-cash-flow
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Has Consensus Price Target of $28.90 According to Analysts
October 13, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31114158
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT) and Viking Therapeutics (VKTX)
October 9, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/FDMT/pressreleases/5059734/analysts-offer-insights-on-healthcare-companies-4d-molecular-therapeutics-fdmt-and-viking-therapeutics-vktx/
See More 4D Molecular Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 4D Molecular Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 4D Molecular Therapeutics and other key companies, straight to your email.

About 4D Molecular Therapeutics

4D Molecular Therapeutics (NASDAQ:FDMT) is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases. The company uses its Therapeutic Vector Evolution platform to engineer adeno-associated virus (AAV) vectors designed to deliver genetic medicines to specific tissues, including the eye and lungs.

Its investigational pipeline includes 4D-150, an intravitreal gene therapy being developed for retinal diseases such as wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, an inhaled gene therapy intended to deliver functional CFTR genes to the lungs of people with cystic fibrosis. These products remain investigational and have not been approved for commercial use.

Founded in 2013, 4D Molecular Therapeutics is headquartered in Emeryville, California, and conducts research and clinical development activities primarily in the United States. The company was co-founded by David Kirn, who has served as its chief executive officer, and has built its business around applying engineered AAV vectors to address diseases that may benefit from targeted gene delivery.

View 4D Molecular Therapeutics Profile
Earnings Tools